Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs01:28

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[An unusual cause of a decline in general health in a very old person].

Revue medicale de Liege·2021
Same author

[Iron deficiency in adults : to understand what biological evaluation should be carried out].

Revue medicale de Liege·2020
Same author

Unsuspected Alzheimer disease in a patient with Multiple sclerosis and progressive aphasia.

Multiple sclerosis and related disorders·2020
Same author

[Psychomotor disadaptation syndrome].

Revue medicale de Liege·2020
Same author

Multifactorial immunodeficiency in frail elderly patients: Contributing factors and management.

Medecine et maladies infectieuses·2019
Same author

Type A competitiveness traits correlate with downregulation of c-Fos expression in patients with type 1 diabetes.

Diabetes & metabolism·2018
Same journal

[Atypical low back pain].

La Revue de medecine interne·2026
Same journal

[Polycythemia associated chronic haemolysis].

La Revue de medecine interne·2026
Same journal

[Persistent headaches in a 55 year-old man].

La Revue de medecine interne·2026
Same journal

[Abdominal pain, fever and arthralgia in a 49-year-old woman].

La Revue de medecine interne·2026
Same journal

[Cardiorespiratory functional disorders: A transnosologic approach].

La Revue de medecine interne·2026
Same journal

[Diagnostic evaluation for suspected polycythemia].

La Revue de medecine interne·2026
See all related articles

Related Experiment Video

Updated: Jun 24, 2026

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

[Antidepressant use in demented elderly subjects: current data].

C Bélicard-Pernot1, P Manckoundia, E Ponavoy

  • 1Service de médecine interne gériatrie, centre de Champmaillot, CHU de Dijon, 2 rue Jules-Violle, Dijon cedex, France.

La Revue De Medecine Interne
|March 21, 2009
PubMed
Summary
This summary is machine-generated.

Antidepressants may worsen dementia, especially in frail elderly patients. Citalopram and moclobemide show promise for treating depression and behavioral symptoms in dementia with fewer risks.

Related Experiment Videos

Last Updated: Jun 24, 2026

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

Area of Science:

  • Geriatric Medicine
  • Neuroscience
  • Psychiatry

Context:

  • Depression and behavioral and psychological symptoms of dementia (BPSD) accelerate cognitive and functional decline.
  • Elderly patients, particularly the frail and those over 75, are underrepresented in clinical trials for dementia treatments.
  • Selective serotonin reuptake inhibitors (SSRIs) carry risks in the elderly, necessitating careful consideration.

Purpose:

  • To evaluate the benefit-risk ratio of antidepressants for depression and BPSD in dementia patients.
  • To identify antidepressants with a favorable safety profile and efficacy in demented elderly individuals.
  • To highlight the need for further research on antidepressant use in Alzheimer's disease and other dementias.

Summary:

  • Antidepressants significantly impact dementia progression, increasing cognitive and functional decline.
  • Current data on the efficacy and safety of antidepressants in dementia patients, especially the frail elderly, is limited.
  • Citalopram and moclobemide demonstrate potential for treating depression and BPSD in dementia with a lower risk of adverse events.

Impact:

  • Physicians require clear guidance on antidepressant selection for elderly dementia patients.
  • Further studies are crucial to establish the effectiveness and safety of antidepressants in this vulnerable population.
  • Improved management of depression and BPSD can enhance the quality of life and prognosis for individuals with dementia.